TipRanks
Agios Pharma (GB:0HB0)
LSE:0HB0
UK Market
0HB0
Agios Pharma
RESEARCH TOOLSreports

Agios Pharma (0HB0) Share Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

0HB0 Analyst Ratings

Strong Buy
6Ratings
Strong Buy
5 Buy
1 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Agios
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0HB0 Stock 12 Month Forecast

Average Price Target

$45.20
▲(34.36% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Agios Pharma in the last 3 months. The average price target is $45.20 with a high forecast of $55.00 and a low forecast of $32.00. The average price target represents a 34.36% change from the last price of $33.64.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","41":"$41","56":"$56","33.5":"$33.5","48.5":"$48.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$45.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$32.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,33.5,41,48.5,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.83,34.535384615384615,36.24076923076923,37.94615384615385,39.65153846153846,41.356923076923074,43.06230769230769,44.76769230769231,46.473076923076924,48.178461538461534,49.88384615384615,51.58923076923077,53.29461538461538,{"y":55,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.83,33.78153846153846,34.73307692307692,35.684615384615384,36.636153846153846,37.58769230769231,38.53923076923077,39.49076923076923,40.44230769230769,41.393846153846155,42.34538461538462,43.29692307692308,44.24846153846154,{"y":45.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.83,32.76615384615384,32.70230769230769,32.638461538461534,32.574615384615385,32.51076923076923,32.44692307692308,32.38307692307692,32.31923076923077,32.255384615384614,32.191538461538464,32.12769230769231,32.06384615384616,{"y":32,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":41.18,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.17,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.68,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.121,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.018,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.091,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.15,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.26,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.08,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.374,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.99,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.83,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$55.00Average Price Target$45.20Lowest Price Target$32.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on GB:0HB0
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$55
Buy
63.50%
Upside
Initiated
10/30/26
Agios Pharmaceuticals assumed with a Buy at H.C. WainwrightAgios Pharmaceuticals assumed with a Buy at H.C. Wainwright
Citi Analyst forecast on GB:0HB0
Samantha Semenkow
Citi
Citi
$52
Buy
54.58%
Upside
Reiterated
10/28/26
Citi Keeps Their Buy Rating on Agios Pharma (AGIO)
RBC Capital Analyst forecast on GB:0HB0
Luca Issi
RBC Capital
RBC Capital
$32
Hold
-4.88%
Downside
Reiterated
10/08/26
Agios Pharma (AGIO) Gets a Hold from RBC Capital
Truist Financial Analyst forecast on GB:0HB0
Gregory Renza
Truist Financial
Truist Financial
$39→$37
Buy
9.99%
Upside
Reiterated
10/07/26
Agios Pharmaceuticals price target lowered to $37 from $39 at TruistAgios Pharmaceuticals price target lowered to $37 from $39 at Truist
Bank of America Securities Analyst forecast on GB:0HB0
Alec Stranahan
Bank of America Securities
Bank of America Securities
$50
Buy
48.63%
Upside
Reiterated
10/06/26
Analysts Offer Insights on Healthcare Companies: Agios Pharma (NASDAQ: AGIO), Korro Bio (NASDAQ: KRRO) and HeartBeam (NASDAQ: BEAT)
TD Cowen Analyst forecast on GB:0HB0
Marc Frahm
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/03/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Agios Pharma (NASDAQ: AGIO), Novavax (NASDAQ: NVAX) and Keros Therapeutics (NASDAQ: KROS)
Goldman Sachs Analyst forecast on GB:0HB0
Salveen Richter
Goldman Sachs
Goldman Sachs
$32
Hold
-4.88%
Downside
Reiterated
07/21/26
Analysts Offer Insights on Healthcare Companies: Agios Pharma (NASDAQ: AGIO) and Imunon (NASDAQ: IMNN)
Leerink Partners Analyst forecast on GB:0HB0
Andrew Berens
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
07/07/26
Analysts Offer Insights on Healthcare Companies: Oncology Institute (NASDAQ: TOI) and Agios Pharma (NASDAQ: AGIO)
J.P. Morgan Analyst forecast on GB:0HB0
Tessa Romero
J.P. Morgan
J.P. Morgan
$36→$31
Hold
-7.85%
Downside
Assigned
06/11/26
Analysts Are Neutral on Top Healthcare Stocks: Stevanato Group (STVN), Agios Pharma (AGIO)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on GB:0HB0
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$55
Buy
63.50%
Upside
Initiated
10/30/26
Agios Pharmaceuticals assumed with a Buy at H.C. WainwrightAgios Pharmaceuticals assumed with a Buy at H.C. Wainwright
Citi Analyst forecast on GB:0HB0
Samantha Semenkow
Citi
Citi
$52
Buy
54.58%
Upside
Reiterated
10/28/26
Citi Keeps Their Buy Rating on Agios Pharma (AGIO)
RBC Capital Analyst forecast on GB:0HB0
Luca Issi
RBC Capital
RBC Capital
$32
Hold
-4.88%
Downside
Reiterated
10/08/26
Agios Pharma (AGIO) Gets a Hold from RBC Capital
Truist Financial Analyst forecast on GB:0HB0
Gregory Renza
Truist Financial
Truist Financial
$39→$37
Buy
9.99%
Upside
Reiterated
10/07/26
Agios Pharmaceuticals price target lowered to $37 from $39 at TruistAgios Pharmaceuticals price target lowered to $37 from $39 at Truist
Bank of America Securities Analyst forecast on GB:0HB0
Alec Stranahan
Bank of America Securities
Bank of America Securities
$50
Buy
48.63%
Upside
Reiterated
10/06/26
Analysts Offer Insights on Healthcare Companies: Agios Pharma (NASDAQ: AGIO), Korro Bio (NASDAQ: KRRO) and HeartBeam (NASDAQ: BEAT)
TD Cowen Analyst forecast on GB:0HB0
Marc Frahm
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/03/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Agios Pharma (NASDAQ: AGIO), Novavax (NASDAQ: NVAX) and Keros Therapeutics (NASDAQ: KROS)
Goldman Sachs Analyst forecast on GB:0HB0
Salveen Richter
Goldman Sachs
Goldman Sachs
$32
Hold
-4.88%
Downside
Reiterated
07/21/26
Analysts Offer Insights on Healthcare Companies: Agios Pharma (NASDAQ: AGIO) and Imunon (NASDAQ: IMNN)
Leerink Partners Analyst forecast on GB:0HB0
Andrew Berens
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
07/07/26
Analysts Offer Insights on Healthcare Companies: Oncology Institute (NASDAQ: TOI) and Agios Pharma (NASDAQ: AGIO)
J.P. Morgan Analyst forecast on GB:0HB0
Tessa Romero
J.P. Morgan
J.P. Morgan
$36→$31
Hold
-7.85%
Downside
Assigned
06/11/26
Analysts Are Neutral on Top Healthcare Stocks: Stevanato Group (STVN), Agios Pharma (AGIO)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AORTArtivion
MDWDMediwound
IMUXImmunic
RZLTRezolute
DFTXDefinium Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Agios Pharma

3 Months
Marc FrahmTD Cowen
Success Rate
14/23 ratings generated profit
61%
Average Return
+3.83%
Copying Marc Frahm's trades and holding each position for 3 Months would result in 60.87% of your transactions generating a profit, with an average return of +3.83% per trade.
1 Year
Gregory RenzaTruist Financial
Success Rate
17/30 ratings generated profit
57%
Average Return
+12.97%
Copying Gregory Renza's trades and holding each position for 1 Year would result in 56.67% of your transactions generating a profit, with an average return of +12.97% per trade.
2 Years
Gregory RenzaTruist Financial
Success Rate
18/30 ratings generated profit
60%
Average Return
+6.62%
Copying Gregory Renza's trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +6.62% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0HB0 Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
7
6
4
2
2
Buy
15
20
18
14
5
Hold
8
7
6
3
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
30
33
28
19
8
In the current month, 0HB0 has received 7 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 0HB0 average Analyst price target in the past 3 months is 45.20.
Each month's total comprises the sum of three months' worth of ratings.

0HB0 Financial Forecast

0HB0 Earnings Forecast

Next quarter’s earnings estimate for 0HB0 is -$1.24 with a range of -$1.64 to -$1.06. The previous quarter’s EPS was -$1.69. 0HB0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0HB0 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0HB0 is -$1.24 with a range of -$1.64 to -$1.06. The previous quarter’s EPS was -$1.69. 0HB0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0HB0 has Performed in-line its overall industry.

0HB0 Sales Forecast

Next quarter’s sales forecast for 0HB0 is $51.65M with a range of $47.00M to $55.38M. The previous quarter’s sales results were $44.74M. 0HB0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0HB0 has Performed in-line its overall industry.
Next quarter’s sales forecast for 0HB0 is $51.65M with a range of $47.00M to $55.38M. The previous quarter’s sales results were $44.74M. 0HB0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0HB0 has Performed in-line its overall industry.

0HB0 Stock Forecast FAQ

What is GB:0HB0’s average 12-month price target, according to analysts?
Based on analyst ratings, Agios Pharma’s 12-month average price target is 45.20.
    What is GB:0HB0’s upside potential, based on the analysts’ average price target?
    Agios Pharma has 34.36% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Agios Pharma a Buy, Sell or Hold?
          Agios Pharma has a consensus rating of Strong Buy, which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Agios Pharma’s share price target?
            The average share price target for Agios Pharma is 45.20. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $55.00 ,and the lowest forecast is $32.00. The average share price target represents 34.36% Increase from the current price of $33.64.
              What do analysts say about Agios Pharma?
              Agios Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of Agios Pharma?
                To buy shares of GB:0HB0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.